Five-year clinical effects of donor bone marrow cells infusions in kidney allograft recipients improved graft function and higher graft survival

Chimerism

Volumn 4, Issue 3, 2013, Pages

  Solgi, Ghasem ^a   Gadi, Vijayakrishna ^b   Paul, Biswajit ^b   Mytilineos, Joannis ^c   Pourmand, Gholamreza ^d   Mehrsai, Abdolrasoul ^d   Ranjbar, Moslem ^e   Mohammadnia, Mousa ^f   Nikbin, Behrouz ^e   Amirzargar, Ali Akbar ^e  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Fred Hutchinson Cancer Research Center   (United States)

^c German Red Cross Blood Transfusion Service Baden Württemberg Hessen and University Hospital Ulm   (Germany)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Donor bone marrow infusion; Kidney allograft; Microchimerism

Indexed keywords

CD34 ANTIGEN; CD4 ANTIGEN; CYCLOSPORIN A; HLA ANTIBODY; INTERLEUKIN 2 RECEPTOR ALPHA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; BONE MARROW TRANSPLANTATION; CD4+ CD25+ FOXP3+ T LYMPHOCYTE; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DONOR BONE MARROW CELL INFUSION; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT REJECTION; LIVING DONOR; MICROCHIMERISM; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SURVIVAL TIME; T LYMPHOCYTE; THERAPY EFFECT;

EID: 84880426667     PISSN: 19381956     EISSN: 19381964     Source Type: Journal    
DOI: 10.4161/chim.24719     Document Type: Article

References (42)

1. Starzl TE Demetris AJ, Trucco M, Ramos H, Zeevi A, Rudert WA, et al. Systemic chimerism in human female recipients of male livers. Lancet 1992; 340:876-7; PMID:1357298; http://dx.doi.org/10.1016/0140-6736(92)93286-V.
2. Starzl TE, Demetris AJ, Trucco M, Zeevi A, Ramos H, Terasaki P, et al. Chimerism and donor-specific nonre-activity 27 to 29 years after kidney allotransplantation. Transplantation 1993; 55:1272-7; PMID:8516813; http://dx.doi.org/10.1097/00007890-199306000-00012.
3. Pujal JM. Should microchimerism turn into rejection prophylactics? Expert Rev Mol Diagn 2010; 10:107-18; PMID:20014925; http://dx.doi.org/10.1586/erm.09.79.
4. Solgi G, Mytilineos J, Gadi V, Paul B, Pourmand G, Mehrsai A, et al. Donor-derived peripheral mononuclear cell DNA is associated with stable kidney allograft function: a randomized controlled trial. Chimerism 2011; 2:102-10; PMID:22509426; http://dx.doi.org/10.4161/chim.2.4.19095.
5. Starzl TE. Chimerism and tolerance in transplantation. Proc Natl Acad Sci U S A 2004; 101(Suppl 2):14607-14; PMID:15319473; http://dx.doi.org/10.1073/pnas.0404829101.
6. Starzl TE. Acquired immunologic tolerance: with particular referece to transplantation. Immunol Res 2007; 38:6-41; PMID:17917005; http://dx.doi.org/10.1007/s12026-007-0001-7.
7. Lechler RI, Garden OA, Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol 2003; 3:147-58; PMID:12563298; http://dx.doi.org/10.1038/nri1002.
8. De Pauw L, Toungouz M, Goldman M. Infusion of donor-derived hematopoietic stem cells in organ transplantation: clinical data. Transplantation 2003; 75(Suppl):46S-9S; PMID:12819491; http://dx.doi. org/10.1097/01.TP.0000067952.60639.1B.
9. Garcia-Morales R, Esquenazi V, Zucker K, Gomez CI, Fuller L, Carreno M, et al. An assessment of the effects of cadaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometry. Transplantation 1996; 62:1149-60; PMID:8900317; http://dx.doi.org/10.1097/00007890-199610270-00021.
10. rd, Roth D, et al. Six-year clini-cal effect of donor bone marrow infusions in renal transplant patients. Transplantation 2001; 71:827-35; PMID:11349712; http://dx.doi.org/10.1097/00007890-200104150-00002.
11. Ciancio G, Burke GW, Garcia-Morales R, Suzart K, Rosen A, Ricordi C, et al. Effect of living-related donor bone marrow infusion on chimerism and in vitro immu-noregulatory activity in kidney transplant recipients. Transplantation 2002; 74:488-96; PMID:12352907; http://dx.doi.org/10.1097/00007890-200208270-00010.
12. Spitzer TR, Delmonico F, Tolkoff-Rubin N, McAfee S, Sackstein R, Saidman S, et al. Combined histocompat-ibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft toler-ance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68:480-4; PMID:10480403; http://dx.doi.org/10.1097/00007890-199908270-00006.
13. Garcia-Morales R, Carreno M, Mathew J, Cirocco R, Zucker K, Ciancio G, et al. Continuing obser-vations on the regulatory effects of donor-specif-ic bone marrow cell infusions and chimerism in kidney transplant recipients. Transplantation 1998; 65:956-65; PMID:9565101; http://dx.doi.org/10.1097/00007890-199804150-00016.
14. Garcia-Morales R, Carreno M, Mathew J, Zucker K, Cirocco R, Ciancio G, et al. The effects of chimeric cells following donor bone marrow infusions as detect-ed by PCR-flow assays in kidney transplant recipients. J Clin Invest 1997; 99:1118-29; PMID:9062371; http://dx.doi.org/10.1172/JCI119240.
15. Cirocco RE, Carreño MR, Mathew JM, Garcia-Morales RO, Fuller L, Esquenazi V, et al. FoxP3 mRNA tran-scripts and regulatory cells in renal transplant recipients 10 years after donor marrow infusion. Transplantation 2007; 83:1611-9; PMID:17589345; http://dx.doi.org/10.1097/01.tp.0000266908.37446.02.
16. Mathew JM, Garcia-Morales RO, Carreno M, Jin Y, Fuller L, Blomberg B, et al. Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation. Transpl Immunol 2003; 11:307-21; PMID:12967784; http://dx.doi.org/10.1016/S0966-3274(03)00056-X.
17. Mathew JM, Miller J. Immunoregulatory role of chi-merism in clinical organ transplantation. Bone Marrow Transplant 2001; 28:115-9; PMID:11509928; http://dx.doi.org/10.1038/sj.bmt.1703110.
18. Mathew JM, Garcia-Morales R, Fuller L, Rosen A, Burke GW, Ciancio G, et al. Cells of donor phenotype present in renal transplant recipients infused with donor marrow: potent regulators of antidonor immune responses of the recipient. Transplant Proc 2001; 33:127-8; PMID:11266739; http://dx.doi.org/10.1016/S0041-1345(00)01937-0.
19. Millan MT, Shizuru JA, Hoffmann P, Dejbakhsh-Jones S, Scandling JD, Grumet FC, et al. Mixed chimerism and immunosuppressive drug with-drawal after HLA-mismatched kidney and hema-topoietic progenitor transplantation. Transplantation 2002; 73:1386-91; PMID:12023614; http://dx.doi.org/10.1097/00007890-200205150-00005.
20. Wood K, Sachs DH. Chimerism and transplantation tolerance: cause and effect. Immunol Today 1996; 17:584-7, discussion 588; PMID:8991291; http://dx.doi.org/10.1016/S0167-5699(96)10069-4.
21. Cosimi AB, Sachs DH. Mixed chimerism and trans-plantation tolerance. Transplantation 2004; 77:943-6; PMID:15077044; http://dx.doi.org/10.1097/01.TP.0000117779.23431.3F.
22. Bühler LH, Spitzer TR, Sykes M, Sachs DH, Delmonico FL, Tolkoff-Rubin N, et al. Induction of kidney allograft tolerance after transient lympho-hematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74:1405-9; PMID:12451240; http://dx.doi.org/10.1097/00007890-200211270-00011.
23. Ranjbar M, Solgi G, Mohammadnia M, Nikbin B, Pourmand G, Ansaripour B, et al. Regulatory T-cell subset analysis and profile of interleukin (IL)-10, IL-17 and interferon-gamma cytokine-producing cells in kidney allograft recipients with donor cells infusion. Clin Exp Nephrol 2012; 16:636-46; PMID:22314659; http://dx.doi.org/10.1007/s10157-012-0591-9.
24. Mohammadnia M, Solgi G, Ranjbar M, Shahrestani T, Edalat R, Razavi A, et al. Serum levels of interleukin (IL)-10, IL-17, transforming growth factor (TGF)-β1, and interferon-γ cytokines and expression levels of IL-10 and TGF-β1 genes in renal allograft recipients after donor bone marrow cell infusion. Transplant Proc 2011; 43:495-9; PMID:21440743; http://dx.doi.org/10.1016/j.transproceed.2011.01.005.
25. Solgi G, Pourmand G, Mehrsai A, Taherimahmoudi M, Nicknam MH, Ebrahimi Rad MR, et al. Anti-HLA antibodies and kidney allograft outcomes in recipients with donor bone marrow cell infusion. Iran J Immunol 2010; 7:18-29; PMID:20371916.
26. Solgi G, Amirzagar AA, Pourmand G, Mehrsai AR, Taherimahmoudi M, Baradaran N, et al. TH1/TH2 cytokines and soluble CD30 levels in kidney allograft patients with donor bone marrow cell infusion. Transplant Proc 2009; 41:2800-4; PMID:19765439; http://dx.doi.org/10.1016/j.transproceed.2009.07.053.
27. Fontes P, Rao AS, Demetris AJ, Zeevi A, Trucco M, Carroll P, et al. Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet 1994; 344:151-5; PMID:7912764; http://dx.doi.org/10.1016/S0140-6736(94)92756-1.
28. Shapiro R, Rao AS, Fontes P, Jordan M, Scantlebury VP, Vivas C, et al. Combined kidney/bone marrow transplantation-evidence of augmentation of chimerism. Transplantation 1995; 59:306-9; PMID:7839456.
29. Shapiro R, Rao AS, Fontes P, Zeevi A, Jordan M, Scantlebury VP, et al. Combined simultaneous kidney/bone marrow transplantation. Transplantation 1995; 60:1421-5; PMID:8545868; http://dx.doi.org/10.1097/00007890-199560120-00009.
30. Rao AS, Shapiro R, Corry R, Dodson F, Abu-Elmagd K, Jordan M, et al. Adjuvant bone marrow infusion in clinical organ transplant recipients. Transplant Proc 1998; 30:1367-8; PMID:9636554; http://dx.doi.org/10.1016/S0041-1345(98)00277-2.
31. Shapiro R, Starzl TE. Bone marrow augmentation in renal transplant recipients. Transplant Proc 1998; 30:1371-4; PMID:9636556; http://dx.doi.org/10.1016/S0041-1345(98)00279-6.
32. Shapiro R, Rao AS, Corry RJ, Valenti M, Zeevi A, Jordan ML, et al. Kidney transplantation with bone marrow augmentation: five-year outcomes. Transplant Proc 2001; 33:1134-5; PMID:11267224; http://dx.doi.org/10.1016/S0041-1345(00)02461-1.
33. Langan LL, Park LP, Hughes TL, Irish A, Luxton G, Witt CS, et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associ-ated with poor kidney graft survival. Am J Transplant 2007; 7:847-56; PMID:17391128; http://dx.doi.org/10.1111/j.1600-6143.2006.01691.x.
34. Pelzl S, Opelz G, Wiesel M, Schnülle P, Schönemann C, Döhler B, et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002; 73:3-6; PMID:11792970; http://dx.doi.org/10.1097/00007890-200201150-00002.
35. Slavcev A, Lácha J, Honsová E, Sajdlová H, Lodererová A, Vitko S, et al. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection. Transpl Immunol 2005; 14:117-21; PMID:15935302; http://dx.doi.org/10.1016/j.trim.2005.03.014.
36. Süsal C, Döhler B, Opelz G. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Hum Immunol 2009; 70:569-73; PMID:19375472; http://dx.doi.org/10.1016/j.humimm.2009.04.013.
37. Worthington JE, Martin S, Al-Husseini DM, Dyer PA, Johnson RW. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75:1034-40; PMID:12698094; http://dx.doi.org/10.1097/01.TP.0000055833.65192.3B.
38. Cardarelli F, Pascual M, Tolkoff-Rubin N, Delmonico FL, Wong W, Schoenfeld DA, et al. Prevalence and significance of anti-HLA and donor-specific antibod-ies long-term after renal transplantation. Transpl Int 2005; 18:532-40; PMID:15819801; http://dx.doi.org/10.1111/j.1432-2277.2005.00085.x.
39. Chen Y, Tai Q, Hong S, Kong Y, Shang Y, Liang W, et al. Pretransplantation soluble CD30 level as a predictor of acute rejection in kidney transplanta-tion: a meta-analysis. Transplantation 2012; 94:911-8; PMID:23052636; http://dx.doi.org/10.1097/TP.0b013e31826784ad.
40. Hirt-Minkowski P, Roth M, Hönger G, Amico P, Hopfer H, Schaub Soluble CD30 correlates with clinical but not subclinical renal allograft rejection. Transpl Int 2013; 26:75-83; PMID:23137306; http://dx.doi.org/10.1111/j.1432-2277.2012.01578.x.
41. Solgi G, Furst D, Mytilineos J, Pourmand G, Amirzargar AA. Clinical relevance of pre and post transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA. Transpl Immunol 2012; 26:81-7; PMID:22182633; http://dx.doi.org/10.1016/j. trim.2011.12.002.
42. Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012; 8:348-57; PMID:22508180; http://dx.doi.org/10.1038/nrne-ph.2012.81.